Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02690064 · ClinicalTrials.gov registry record · NA
Mechanisms for Vascular Dysfunction and Exercise Tolerance in CF
A NA study of Cystic Fibrosis, sponsored by Augusta University.
- Active
- Registry status
- NA
- Development phase
- 13
- Enrollment target
- 1
- Study location
NCT02690064: Active NA study of Cystic Fibrosis, sponsored by Augusta University.
NCT02690064 is a NA study of Cystic Fibrosis that is active but no longer recruiting, run by Augusta University. The registered enrollment target is 13 participants, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02690064, a NA study of Cystic Fibrosis, is active but no longer recruiting, sponsored by Augusta University.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 13 participants
- Enrollment target
- 1
- Study location
Study Summary
Cystic fibrosis has many health consequences. A reduction in the ability to perform exercise in patients with CF is related to greater death rates, steeper decline in lung function, and more frequent lung infections. However, the physiological mechanisms for this reduced exercise capacity are unknown. The investigators recently published the first evidence of systemic vascular dysfunction in patients with CF. Therefore, it is reasonable to suspect that the blood vessels are involved with exercise intolerance in CF. This study will look at how and if oxidative stress contributes to both artery dysfunction and exercise intolerance in CF.
Primary Outcome
Flow-Mediated Dilation will be determined at baseline and 2 hours following acute antioxidant treatment
Conditions Studied
Interventions
- OTHER Placebo
- DIETARY_SUPPLEMENT Acute Antioxidant
- DIETARY_SUPPLEMENT Chronic Antioxidant
Study Locations (1)
Georgia
- Georgia Prevention Institute - Augusta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2015-04 |
| Est. Completion | 2027-01 |
| Phase | NA |
What the registry record for NCT02690064 still lists
NCT02690064 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Cystic Fibrosis appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT02690064 reports a single indexed study location in Georgia.
Frequently Asked Questions
What is clinical trial NCT02690064 about?
NCT02690064 is a clinical study titled "Mechanisms for Vascular Dysfunction and Exercise Tolerance in CF". Cystic fibrosis has many health consequences. A reduction in the ability to perform exercise in patients with CF is related to greater death rates, steeper decline in lung function, and more frequent lung infections. However, the physiological mechanisms for this reduced exercise capacity are unknow...
What is the current status of trial NCT02690064?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 13 participants. The study started on 2015-04. Estimated completion is 2027-01.
What conditions does trial NCT02690064 study?
This clinical trial studies the following conditions: Cystic Fibrosis.
What interventions are being tested in trial NCT02690064?
The interventions under investigation include: Placebo (OTHER), Acute Antioxidant (DIETARY_SUPPLEMENT), Chronic Antioxidant (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT02690064?
This trial is sponsored by Augusta University, which has 106 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02690064 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cystic Fibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02690064's enrollment target sits among peer trials
13 151st of 169 higher than 19 of 169 other Cystic Fibrosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cystic Fibrosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Exercise in Child Health
RECRUITING · NA
-
A Pilot and Feasibility Study to Evaluate High vs Low Glycemic Index Mixed Meal Tolerance Test in Adolescents and Young Adults With Cystic Fibrosis
RECRUITING · NA
-
FEED-Cystic Fibrosis (FEED-CF)
RECRUITING · NA
-
The Effects of a Low Glycemic Load Diet on Dysglycemia and Body Composition in Adults With Cystic Fibrosis-Related Diabetes
RECRUITING · NA
-
Skin-interfaced Colorimetric Bifluidic Sweat Sensor Device for the Diagnosis of Cystic Fibrosis (CF)
RECRUITING · NA
-
Lung Transplant READY CF 2: CARING CF Ancillary RCT
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia